See the published version of this preprint at BMC Gastroenterology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Jinlin Yang
Sichuan University West China Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
To investigate the effect of albumin infusion in cirrhotic patients admitted for acute gastrointestinal bleeding.
Methods
Medical records of cirrhotic patients who admitted due to acute gastrointestinal bleeding through January 2009 to December 2018 were systemically reviewed. Clinical data and the total amount of albumin and red blood cell used during hospitalization were recorded. For patients with rebleeding, the amount of albumin and red blood cell used before rebleeding was also documented. The primary outcome was the occurrence of rebleeding and the second outcome was in-hospital mortality. Univariate and multivariate logistic analysis were performed to identify risk factors associated with rebleeding and in-hospital mortality.
Results
A total of 2239 cirrhotic patients were included in the analysis. There were 245 episodes of in-patient rebleeding occurred, while 135 patients died. Overall, more red blood cells and albumin were prescribed to patients who suffered rebleeding. In terms of the amount before rebleeding, the red blood cell was higher in patients with rebleeding, but the albumin infusion were similar. In the multivariate model, the albumin infusion was an independent risk factor associated with rebleeding (adjusted OR for ≤40g, 0.385 [0.252-0.588], p<0.001; OR for >40g, 0.295 [0.169-0.514], p<0.001). The use of albumin more than 40g during hospitalization reduces the risk of in-patient mortality (adjusted OR for ≤40g, 0.730 [0.375-1.423], p=0.356; OR for >40g, 0.389 [0.180-0.838], p=0.016).
Conclusions
Albumin infusion could reduce risk of in-hospital rebleeding. Moreover, more than 40g albumin infusion decrease numbers of mortality in cirrhosis admitted for acute gastrointestinal bleeding.
Keywords
albumin, cirrhosis, gastrointestinal bleeding, portal hypertension
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Gastroenterology.
No community comments so far
Editorial decision: Accept
On 08 Jun, 2020
Editor assigned
On 30 Apr, 2020
Editor invited
On 29 Apr, 2020
Submission checks complete
On 07 Jan, 2020
No comments provided
Editorial decision: Major revision
On 19 Apr, 2020
Editor assigned
On 16 Apr, 2020
Submission checks complete
On 15 Apr, 2020
Editor invited
On 15 Apr, 2020
Version 1
Posted 10 Jan, 2020
No comments provided
Editorial decision: Major revision
On 13 Mar, 2020
Review #2 received
Received 08 Mar, 2020
Review #1 received
Received 24 Jan, 2020
Reviewer #2 agreed
On 14 Jan, 2020
Editor assigned
On 11 Jan, 2020
Reviewers invited
Invitations sent on 11 Jan, 2020
Reviewer #1 agreed
On 11 Jan, 2020
Submission checks complete
On 08 Jan, 2020
Editor invited
On 08 Jan, 2020
First submitted
On 24 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
Learn more about our company.
See the published version of this preprint at BMC Gastroenterology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Jinlin Yang
Sichuan University West China Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Gastroenterology.
No community comments so far
Editorial decision: Accept
On 08 Jun, 2020
Editor assigned
On 30 Apr, 2020
Editor invited
On 29 Apr, 2020
Submission checks complete
On 07 Jan, 2020
No comments provided
Editorial decision: Major revision
On 19 Apr, 2020
Editor assigned
On 16 Apr, 2020
Submission checks complete
On 15 Apr, 2020
Editor invited
On 15 Apr, 2020
Version 1
Posted 10 Jan, 2020
No comments provided
Editorial decision: Major revision
On 13 Mar, 2020
Review #2 received
Received 08 Mar, 2020
Review #1 received
Received 24 Jan, 2020
Reviewer #2 agreed
On 14 Jan, 2020
Editor assigned
On 11 Jan, 2020
Reviewers invited
Invitations sent on 11 Jan, 2020
Reviewer #1 agreed
On 11 Jan, 2020
Submission checks complete
On 08 Jan, 2020
Editor invited
On 08 Jan, 2020
First submitted
On 24 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Gastroenterology.
Background
To investigate the effect of albumin infusion in cirrhotic patients admitted for acute gastrointestinal bleeding.
Methods
Medical records of cirrhotic patients who admitted due to acute gastrointestinal bleeding through January 2009 to December 2018 were systemically reviewed. Clinical data and the total amount of albumin and red blood cell used during hospitalization were recorded. For patients with rebleeding, the amount of albumin and red blood cell used before rebleeding was also documented. The primary outcome was the occurrence of rebleeding and the second outcome was in-hospital mortality. Univariate and multivariate logistic analysis were performed to identify risk factors associated with rebleeding and in-hospital mortality.
Results
A total of 2239 cirrhotic patients were included in the analysis. There were 245 episodes of in-patient rebleeding occurred, while 135 patients died. Overall, more red blood cells and albumin were prescribed to patients who suffered rebleeding. In terms of the amount before rebleeding, the red blood cell was higher in patients with rebleeding, but the albumin infusion were similar. In the multivariate model, the albumin infusion was an independent risk factor associated with rebleeding (adjusted OR for ≤40g, 0.385 [0.252-0.588], p<0.001; OR for >40g, 0.295 [0.169-0.514], p<0.001). The use of albumin more than 40g during hospitalization reduces the risk of in-patient mortality (adjusted OR for ≤40g, 0.730 [0.375-1.423], p=0.356; OR for >40g, 0.389 [0.180-0.838], p=0.016).
Conclusions
Albumin infusion could reduce risk of in-hospital rebleeding. Moreover, more than 40g albumin infusion decrease numbers of mortality in cirrhosis admitted for acute gastrointestinal bleeding.
Figure 1
Figure 2
Loading...